Sector Update: Health Care Stocks Rise in Monday Afternoon Trading

MT Newswires13:45 ET

Intellia Therapeutics' Nex-z Receives FDA Regenerative Medicine Advanced Therapy Designation

MT Newswires11:02 ET

Intellia's Single-Dose Gene Editing Treatment for ATTR Amyloidosis Gets FDA Fast-Track Approval Boost

BenzingaNov 25 07:32 ET

Express News | Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (Rmat) Designation Granted to Nexiguran Ziclumeran (Nex-Z) for the Treatment of Hereditary Transthyretin (Attr) Amyloidosis With Polyneuropathy

ReutersNov 25 07:30 ET

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (Nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis With Polyneuropathy

Yahoo FinanceNov 25 07:30 ET

Pfizer Meets Amyloidosis Rival as BridgeBio Wins FDA Nod for Attruby

Seeking AlphaNov 23 08:26 ET